Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.15 HKD | -2.97% | -2.61% | -33.12% |
May. 29 | JD.com's Healthcare Arm Shuttering Family Doctor Initiative | MT |
May. 29 | China stocks close marginally higher after IMF upgrades GDP forecasts | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 55% by 2026.
- The company is in a robust financial situation considering its net cash and margin position.
- With regards to fundamentals, the enterprise value to sales ratio is at 1.03 for the current period. Therefore, the company is undervalued.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.48 times its estimated earnings per share for the ongoing year.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-33.12% | 10.67B | B | ||
-37.88% | 13.99B | B- | ||
+12.54% | 6.29B | C | ||
-11.17% | 5.88B | C+ | ||
+75.00% | 4.96B | C | ||
-4.38% | 4.54B | D- | ||
-9.20% | 3.74B | B | ||
-19.40% | 3.16B | C- | ||
-12.15% | 2.85B | C- | ||
-12.99% | 2.53B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 6618 Stock
- Ratings JD Health International Inc.